Corneal Cross Linking

Keratoconus is a sight-stealing disease of the cornea that has had limited treatment options to slow its progression. But now, Cornea Consultants of Albany are happy to become the first surgeons in Northeastern New York to begin using the FDA-approved cross-linking device and medication from Avedro; a groundbreaking treatment that has already begun to change the lives of patients with keratoconus.

Keratoconus thins and steepens the central cornea, which is the clear, outermost layer of the eye. It occurs when the normally round-shaped cornea progressively thins, causing a cone-like bulge to develop. Patients who suffer from keratoconous can experience blurred and distorted vision that is difficult to correct with contact lenses and glasses. The progressive thinning and weakening can often result in significant vision loss and may lead to corneal transplantation. The disease often begins in the teenager years but has been reported to occur as early as six years of age. Our physicians offer comprehensive eye exams with advanced corneal testing to try and catch keratoconus early.

Until now, treatment options for keratoconus have been limited to minimizing the symptoms. With cross-linking, we will be able to slow or even stop the progression of the disease. The FDA approval of this therapeutic treatment comes after years of rigorous research and clinical trials that demonstrated the stabilization of the cornea within three to twelve months after cross-linking.

Cornea Consultants of Albany is always on the cutting-edge of technology and our treatment plan has the opportunity to help stop the progression of keratoconus. The cross-linking system is a significant advancement in science development, and we are eager to help improve our patients’ vision. Please call our office to schedule an appointment to see if cross-linking is right for you.